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Abstract
Exome sequencing constitutes an important technology for the study of human hereditary diseases and cancer. However,
the ability of this approach to identify copy number alterations in primary tumor samples has not been fully addressed. Here
we show that somatic copy number alterations can be reliably estimated using exome sequencing data through a strategy
that we have termed exome2cnv. Using data from 86 paired normal and primary tumor samples, we identified losses and
gains of complete chromosomes or large genomic regions, as well as smaller regions affecting a minimum of one gene.
Comparison with high-resolution comparative genomic hybridization (CGH) arrays revealed a high sensitivity and a low
number of false positives in the copy number estimation between both approaches. We explore the main factors affecting
sensitivity and false positives with real data, and provide a side by side comparison with CGH arrays. Together, these results
underscore the utility of exome sequencing to study cancer samples by allowing not only the identification of substitutions
and indels, but also the accurate estimation of copy number alterations.
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Introduction
The development of Next Generation Sequencing (NGS)
technologies has allowed the study of the human genome at an
unprecedented level. Whole-genome sequencing (WGS) of several
individuals has been already performed shedding new light on
human variation, genome complexity and molecular mechanisms
of certain hereditary diseases [1,2]. In addition, sequencing of
cancer genomes has revealed a very complex landscape of somatic
mutations [3–5] and has led to the identification of driver genes
responsible for tumor initiation and growth [6–9]. Despite the
utility of WGS to understand human disease, this global approach
is still economically unaffordable for most laboratories and does
not allow the analysis of hundreds or even thousands of samples in
a timely manner. In this regard, the development of technologies
for the capture of specific regions of the genome [10,11], such as
all coding exons or exome, followed by NGS, has proven very
useful for the rapid and economic identification of mutations in
different human hereditary diseases as well as in cancer [12–19].
Due to the high coverage obtained using exome sequencing, this
technique constitutes an interesting approach for the identification
of point mutations and small indels with high accuracy in both
normal and tumor samples.
Point mutations and indels constitute the most frequent
alterations present in a tumor genome [4,5], and the ability to
identify them using exome sequencing represents an important
achievement in cancer genomics. However, cancer cells also
present other type of mutations, including translocations, inver-
sions or changes in copy number, which constitute important
events for tumor development. For instance, copy number
alterations (CNAs) due to either deletion or amplification of
specific regions frequently lead to deletion of tumor suppressor
genes or to the amplification of oncogenes, representing driver
events during tumor development [20–22]. In addition, some
hereditary diseases are caused not by point mutations but by
CNAs resulting in the deletion or amplification of specific genes,
exons or regulatory sequences [23,24]. In fact, a recent study using
WGS has identified a novel CNA in TP53 causing Li-Fraumeni
syndrome [25], reinforcing the importance of CNAs in human
disease. A currently assumed limitation of exome sequencing is its
inability to identify this type of structural variants, and the analysis
of exome data is usually complemented with other technologies,
such as comparative genomic hybridization arrays (aCGH) or high
throughput sequencing at low coverage in order to identify CNAs
[26,27], resulting in the requirement of additional sample material
as well as increases in costs per sample. The importance of CNAs
in human disease implies that the study of human pathologies by
exome sequencing data must be complemented by other
approaches in order to cover this type of variation.
Recent studies have shown that by using depth of coverage of
individual exons, it is possible to identify copy number alterations
in tumor and matched normal tissue exomes [28–32]. However,
these methods can result in the identification of false positive
CNAs due to the inherent variability of the capturing method
and/or sequencing efficiency of certain regions. Therefore, to
analyze the utility of this technique for cancer genomics and to
define the limits of this type of analysis it is necessary to analyze
exome sequencing data obtained from different individuals and
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processed at different times. Furthermore, a side by side
comparison between exome and aCGH data is necessary to
determine the sensitivity and specificity using primary tumors. In
this work, we demonstrate that exome data can be used to detect
tumor-specific CNAs with high accuracy and sensitivity by
analyzing 86 paired normal and primary tumor samples, and
show a high concordance with aCGH data. This work provides
the opportunity to re-analyze existing datasets to extract this




Sequencing and genotyping data for chronic lymphocytic
leukemia (CLL) patients was obtained from the CLL-ICGC
Consortium and are deposited at the European Genome-Phenome
Archive (EGA, http://www.ebi.ac.uk/ega/), which is hosted at
the EBI, under accession number EGAS00000000092.
Exome capture, sequencing and mapping
Three mg of genomic DNA were fragmented to 150–200 bp and
hybridized using a SureSelect Human All Exon 50 Mb Kit
(Agilent) together with the Paired-End Sample Preparation Kit
from Illumina following manufacturers’ protocols. The captured
DNA fragments were sequenced using one lane of a Genome
Analyzer IIx (Illumina) per sample and 76 cycles, resulting in more
than 30 million paired-reads per sample. Reads were aligned to
the reference genome (GRCh37) using BWA-0.5.7 [33] and
Samtools-0.1.7 was used to remove PCR duplicates and to create
BAM files [34].
Analysis of copy number alterations from exome data
For each sample, we counted the number of individual reads
mapped within 50 bp of each of the 212,997 target regions
included in the SureSelect Human All Exon 50 Mb Kit. Then, the
coverage per sample was normalized to Reads mapped Per
Kilobase of probe and per Million of reads mapped (RPKMs)
taking into account the probe length and the total number of reads
mapped within the target regions with mapping quality $30. To
create a reference exome to be compared with individual data, we
calculated for each probe the average RPKMs obtained from 31
female individuals for the analysis of the X chromosome data, and
from 86 different individuals for the analysis of tumor CNAs in
autosomes. The log2 ratio of tumor RPKMs to normal RPKMs
from the same patient was obtained for each exon and processed
using the DNAcopy package [35]. Log2 ratios were smoothed by
DNAcopy and CNAs were detected using default values. Tumor
CNAs were defined as those regions containing a minimum of six
exons, with an average log2 ratio below 20.3 or above 0.3 as
determined by DNAcopy. To remove false positives due to the
presence of consecutive exons with variable capture efficiency, we
performed the following procedure: i) for each exon included in
the CNA region we computed the average RPKMs in all 86
normal samples (RPKMi
N), as well as the standard deviation
(SDi
N) for the RPKMs of that exon in normal samples; ii) then, the
absolute difference between the RPKMs for that exon in the
tumor sample (RPKMi
T) and the average RPKMs for that exon in
normal samples (RPKMi
N) was divided by the standard deviation
obtained from the normal samples (SDi
N); iii) for each potential
CNA the average deviation of all exons included in that region is





















This allows to determine the deviation of tumor RPKMs from
the average of normal samples. Those regions in which the
average deviation was less than 1.5 SDs from the average of
normal samples, and likely representing regions in which the
capture efficiency of those exons was highly variable between
samples, were removed. For the analysis of CNAs using the
ExomeCNV package [28] we used the default parameters, and
DNACopy settings were set to the same ones used before to allow
a direct comparison of results. Tumor CNAs were defined as those
regions containing a minimum of six exons, with an average log2
ratio below20.3 or above 0.3. A CNA was described as supported
by aCGH data when at least two exons were included within the
boundaries obtained by aCGH analysis, and the copy number
status (either loss or gain) was identical between both procedures.
Comparative genomic hybridization arrays
Copy number analysis were performed in all samples hybrid-
izing 1 mg of the test DNA and 1 mg of reference DNA on
SurePrint G3 Human CGH Microarray 1 M (Agilent Technol-
ogies, Santa Clara, USA). The DNA samples hybridized were
from the same preparations used for exome capture and
sequencing. Raw data were generated from scanned images using
Agilent Feature Extraction Software (v10.7). Log2 ratios of
background corrected values for tumor over normal DNA were
calculated. Post-hybridization quality control reports included
DLRspread values, signal intensity, array with DLRspread over
0.3 was considered as low quality and consequently discarded.
Detection of CNA was performed using the Aberration Detection
Method-2 (ADM-2) algorithm implemented within the Agilent’s
genomics suite Genomic Workbench v5.0 with a threshold of 6.5
and a minimum of 5 consecutive probes. T-cell receptor regions
rearranged in some non-tumor cells that might lead to the
identification of false positive gains in the tumor were filtered for
subsequent analysis.
Results
Detection of changes in copy number using exome
sequencing
In exome sequencing, a DNA sample is captured by specific
probes and then subjected to NGS, resulting in the generation of
sequence reads corresponding to the target regions. Therefore, if
there is a difference in copy number between two samples, the
number of reads derived from that particular region should be
different for both samples. However, the introduction of ampli-
fication steps during sample preparation and the limited number
of bait probes which are added to the capture reaction could result
in the saturation of the capturing probes, thereby hampering the
identification of CNAs. In addition, the number of reads produced
by different probes or in different experiments is highly variable
due to several factors: i) the efficiency of the capturing procedure
for a specific probe; ii) the sequencing efficiency for that particular
region; iii) the total number of reads sequenced; and iv) the size of
the target region. The first two factors are inherent to the
technologies used for capturing and sequencing. However, they
should not affect the comparison among samples, as probes with
poor capturing efficiency or regions difficult to sequence should be
Copy Number Estimation from Exome Sequencing
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equal for all samples processed using the same capturing protocol
and sequencing technology. Regarding the last two factors, they
can be easily normalized using a similar solution to that used for
RNAseq experiments [36]. Thus, for any given probe the number
of reads mapped can be expressed as RPKMs (Reads mapped Per
Kilobase of probe and per Million of reads mapped).
Taking into account these considerations, and in order to
determine whether exome sequencing data could be used to
identify copy number changes between different samples, we first
checked whether read coverage in the X chromosome was
different between normal samples derived from males (one copy)
and females (two copies). We counted all sequence reads mapped
in the target regions 650 bp with a mapping quality of more than
30. Following this scheme, we compared the average RPKMs for
55 males and 31 females. We found that the coverage (RPKMs) in
the X chromosome (excluding the pseudoautosomal regions) was
12.1160.19 for males and 23.460.57 for females, very close to the
1:2 ratio expected. In contrast, the coverage in autosomes was
almost identical between both groups (20.8060.12 vs.
20.3960.11). These results confirm previous studies [28–32]
showing that the analysis of exome data can be used to detect
chromosomal deletions in heterozygosity with high accuracy.
To investigate the minimum number of probes necessary to
detect chromosomal deletions using exome sequencing data, and
due to the variability of the exon capture procedure during sample
preparation, we empirically determined this parameter by
comparing real data from males and females. We selected a total
of 6,588 exons that were located in the X chromosome (excluding
the pseudoautosomal regions) and were efficiently captured by this
technology, as they had at least a minimum of two RPKMs in
females. For each individual exon, we calculated the average
RPKMs obtained in females, and used this value as the reference
RPKMs for that particular exon in individuals with two copies of
the X chromosome. Then, for each of the 566,568 exons analyzed
in 86 individuals we calculated the ratio of RPKMs for each
individual exon versus the reference value calculated before. There
was a marked difference in this ratio between males and females
for most individual exons (Figure 1A). In fact, 94% of exons from
males had RPKM ratios which were at less than 21.5 SDs from
the female average for that particular exon, while only 6% of
exons from females were at less than 21.5 SDs. The sensitivity to
detect this change in copy number increased as a larger number of
consecutive exons were used, while the percentage of false positives
decreased (Figure 1B). In this sense, we determined that by using a
minimum of six exons, 99.29% of male loci were at less than 21.5
SDs from the female average, and 99.43% of female loci were at
more than 21.5 SDs, suggesting that these parameters could be
used to detect copy number changes with high sensitivity and a
low false discovery rate.
Identification of tumor-specific CNAs using exome
sequencing data
An important field for the application of technologies allowing
the identification of CNAs is cancer genomics, as a large number
of somatic mutations affecting oncogenes or tumor suppressor
genes involve either amplification or deletion of the corresponding
loci. To determine whether chromosomal gains or losses as well as
smaller CNAs could be detected in tumor samples using exome
sequencing data, we studied 86 CLL samples known to have
changes in copy number by aCGH [8,37]. CLL represents an
interesting model because this tumor type usually has very few
CNAs [8], what allows an accurate estimation of the number of
false positive calls by novel approaches as the one described in this
study. For this aim, we developed a strategy to identify CNAs
using exome data that we called exome2cnv (Figure 2). Thus, for
each single capturing exon we compared the log2 ratio of the
RPKMs obtained from the tumor sample to the RPKMs obtained
from the normal sample, and applied a circular binary segmen-
tation algorithm (DNAcopy) to identify regions potentially lost or
gained in the tumor sample [35]. To reduce the noise introduced
due to exons with poor capturing efficiency, we selected only those
exons having at least two RPKMs in the normal sample from the
same patient (.89% of the exons). For all those cases, in addition
to exome data we also had available aCGH data for tumor and
normal samples (see Material and Methods), what allowed us to
compare the results of the exome2cnv approach in terms of
sensitivity and false positives.
By comparing exome data from the tumor sample with its
matched non-tumor cells we were able to detect several somatic
CNAs affecting autosomes which were also found using aCGH
data (Figure 3 and Tables S1 and S2). They involved homozygous
or heterozygous deletion of large chromosomal regions (in
chromosomes 6, 11, 13, 17 or 20), gains of whole chromosomes
(chromosome 12) or large chromosomal regions (in chromosomes
2, 3, and 4), as well as other smaller regions including deletion of
the RFX7 gene or deletion of six exons of SLC9A9. In addition, we
detected both homozygous and heterozygous deletions of a small
fragment of chromosome 13q14 frequently deleted in CLL tumors
[8,38,39] (Figure 3 and Figure 4) and resulting in the deletion of
two microRNAs (miR15a and miR16-1) frequently lost in this
pathology [38]. Trisomy of chromosome 12, a frequent alteration
present in CLL tumors, was also identified using exome2cnv.
Together, these results show that this procedure allows the
identification of most types of CNAs that might be present in
cancer samples, including heterozygous and homozygous deletions
as well as amplified genomic regions.
Comparison between exome2cnv and aCGH data
To estimate the sensitivity and the number of false positives of
this approach, we compared the data obtained by exome2cnv with
that obtained by aCGH. Thus, using the exome data we identified
387 CNAs out of the 549 detected by aCGH (70%). However, as
previously shown in Figure 1B and due to the variability of exon
capture, it would be necessary to combine at least six exons to
make a reliable CNA call. Using this cutoff for aCGH regions,
only 44 out of the 162 aCGH regions not detected by exome2cnv
fulfilled this criterion, suggesting that the exome2cnv sensitivity to
detect tumor-specific CNAs is more than 89%. In agreement with
these results, analysis of these 86 tumor-normal pairs with a
previously described method [28] resulted in the identification of
22,423 potential CNAs, with more than 18,000 of them
corresponding to single-exon CNAs which were not supported
by aCGH data. These calls likely constitute false positives due to
differences in the capturing efficiency or to a batch effect. In fact,
the introduction of a minimum number of six consecutive exons to
make a call still resulted in more than 80% of calls not being
supported by aCGH data. In this regard, a detailed examination of
these calls revealed than in most cases they were supported by
consecutive exons showing either small RPKMs, high GC content
and high variability between different samples, suggesting poor
reproducibility in the capture efficiency. Calls reporting a putative
gain, an infrequent event in CLL with the exception of
chromosome 12 trisomy, were particularly sensitive to this
variability issue, with more than 95% of the calls not being
supported by aCGH data. Together, these results reinforce the
importance of establishing specific parameters affecting the
performance of exome sequencing-based CNA estimation, such
as minimum number of exons, and to take into account the
Copy Number Estimation from Exome Sequencing
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RPKM variance across normal samples, which are used by the
exome2cnv method described herein.
It is interesting to notice that as CLL cells derive from B-
lymphocytes, which had undergone rearrangement of immuno-
globulin genes during B-cell maturation, we were able to detect in
almost all analyzed cases focal homozygous or heterozygous
deletions in chromosomes 2p11, 14q32.33 and 22q11.22, where
immunoglobulin genes are located (Figure 3). However, when
these regions were omitted from the analysis, we obtained the
same sensitivity, indicating that exome2cnv has enough sensitivity to
detect most oncogenic CNAs. Furthermore, when we compared
the number of exons included in CNAs affecting subchromosomal
regions between the exome2cnv approach and aCGH data, we
obtained a high correlation between both approaches (r2 = 0.99)
(Figure S1), suggesting that CNA boundaries detected by both
methods are highly similar in terms of exons involved in the copy
number change.
On the other hand, we found that more than 86% of the CNAs
detected by exome2cnv overlapped with CNAs detected by aCGH
(819/947). Although it is possible that some of the 128 regions
detected specifically by the exome2cnv approach might constitute
false positives, manual inspection of the aCGH data for these
regions revealed that at least 16 of them could be considered
CNAs present in a subpopulation of CLL cells (Figure 3 and Table
S2 and Figure S2). Furthermore, another 37 of them were located
in loci containing immunoglobulin genes and putatively represent-
ing real CNAs. Together, these data show that using the minimum
threshold of six exons empirically determined before, more than
92% of identified regions might constitute bona fide somatic CNAs.
Discussion
Exome sequencing, using target capture strategies followed by
NGS, is becoming a routine technique for the study of somatic
mutations in tumor samples as well as for the identification of the
genetic alterations responsible for numerous hereditary diseases
[9,14,15,18,40]. Due to the target capture approach, exome
sequencing analysis has limitations to uncover the different types of
variations present in a cancer genome, and its use is mostly limited
to the study of substitutions and small indels. The results presented
herein demonstrate that exome sequencing data can be also used
to estimate copy number alterations with high accuracy, allowing
the identification of somatic CNAs in tumor/normal samples from
cancer patients.
The ability to detect CNAs using exome sequencing data has
been recently proposed [28–32]. However, the real utility of this
approach for the study of cancer exomes requires the analysis of a
Figure 1. Estimation of copy number from exome sequencing data in the X chromosome of males and females. For each individual
exon we calculated the coverage ratio as the ratio of RPKMs for that exon divided by the average RPKMs for that particular exon in females. (A)
Distribution of ratios for more than 566,000 individual exons from either males (blue) or females (red). Effect of the number of consecutive exons
considered for copy number estimation in sensitivity and false discovery rate. (B) For each different number of exons (numbers close to dots), the
sensitivity is expressed as the fraction of male regions detected as copy number one when compared to the female average for the same regions.
False discovery rate was calculated as the fraction of female regions detected as copy number one when compared to the female average for the
same regions.
doi:10.1371/journal.pone.0051422.g001
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larger number of primary tumors. In this study, we have used a
liquid capture technique and the target regions which were
initially designed by the International Cancer Genome Consor-
tium (ICGC) [41] to analyze CNAs in a total of 86 primary CLL
cases using exome sequencing data. We performed a side by side
comparison with traditional CGH technologies in order to
determine the sensitivity of this novel approach. The results
obtained in this initial approach demonstrate that exome2cnv has the
Figure 2. Scheme depicting the strategy used by exome2cnv for detecting CNAs using exome coverage data for a tumor sample and
a normal sample from the same patient. Normalized coverage (RPKMs) is determined for each individual capturing exon, and the ratio tumor/
normal is calculated for each probe. Genome-wide analysis of ratios allows the identification of regions having somatic copy number alterations in
the tumor (red lines).
doi:10.1371/journal.pone.0051422.g002
Figure 3. Comparison of CNAs obtained by exome2cnv and aCGH in 86 CLL cases. CNAs were classified in four different classes represented
by different colors in the figure. CNAs detected by both exome2cnv and aCGH approaches are labeled in yellow; those detected specifically by
exome2cnv are shown in green; CNAs only detected by aCGH are shown in red; and CNAs detected by exome2cnv and considered as subclones by
aCGH or corresponding to immunoglobulin regions are shown in purple. Regions recurrently altered in CLL are indicated on top.
doi:10.1371/journal.pone.0051422.g003
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potential to identify most CNAs affecting exon-containing regions.
Based on our data, the exome2cnv approach would allow the
identification of either long CNAs containing hundreds of genes,
or small regions affecting up to a single gene or a single exon. In
addition, we have determined the proportion of false positives of
this approach, as most researchers would like to know how many
regions identified by exome2cnv are bona fide CNAs, as well as the
parameters affecting the number of false positives. We have shown
that similar to other methods, there is a balance between sensitivity
and false discovery rate, and by increasing the number of exons to
call a CNA it is possible to reduce the number of false positives.
Our procedure differs from other previously described methods in
two basic aspects. First, we empirically determine a minimum
number of exons to make a CNA call and only exons with a
minimum coverage in the normal sample are used in the analysis.
All described methods for the identification of somatic CNAs from
exome-sequencing data, including the one described here, are able
to detect CNAs affecting a single exon. However, due to the
different efficiency in capturing of specific probes or sequencing of
certain genomic regions, side by side comparison of two samples
processed independently might lead to the erroneous classification
of numerous exons as CNAs. In fact, a direct comparison of exon
coverage using previously reported methods results in the
identification of more than 200 single-exon CNAs per case not
supported by aCGH data, suggesting that they constitute false
positives. In our method this effect can be substantially reduced by
using only exons with a good capture efficiency, defined here as
more than 2 RPKMs, and by requiring at least a minimum
number of consecutive exons to make a call, established here as 6
or more consecutive exons. The second difference with previously
reported methods is the use of coverage data from normal samples.
In fact, a common problem during the analysis of samples
Figure 4. Comparison between CNAs detected by exome2cnv and aCGH. Grey dots represent log2 ratios of tumor/normal probe intensities
from aCGH, while black dots show log2 ratios of tumor/normal from exome sequencing data. The local averages determined for exome data (red
lines) and aCGH data (green lines) are shown. (a) Homozygous deletion of a small region of chromosome 13 detected by both approaches. (b)
Detailed view of the same chromosomal region shown in (a).
doi:10.1371/journal.pone.0051422.g004
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captured or sequenced at different times or in different centers is
the inter-sample variability in capture efficiency in specific
regions/probes. Although this variability has a minor effect in
the identification of point-mutations and/or indels, it represents a
common problem for the identification of CNAs, resulting in the
identification of many false positives [28]. In order to reduce the
false discovery rate of this method, we have introduced a step that
takes into account not only the different coverage between tumor
and normal samples, but also the coverage distribution along all
non-tumor samples available. Only those regions supported by
exons whose coverage differ more than 1.5 SDs from the average
coverage of those exons in non-tumor samples are considered as
CNAs. Using this approach, we could confirm that more than
92% of the CNA regions identified using exome2cnv were also
detected using CGH arrays, strongly supporting the utility of this
method for the analysis of CNA in cancer exomes. Together, these
filtering steps are able to reduce the number of false positives CNA
regions identified by exome2cnv, while maintaining a sensibility of
more than 89% to detect CNAs involving at least six exons.
Although a lower number of exons could be used, this would likely
increase the number of false positives. This approach can benefit
the identification of somatic CNAs in tumor/normal samples from
cancer patients, as they usually involve amplification or deletion of
chromosomal regions containing several genes, facilitating their
detection by exome2cnv approach. In fact, the sensibility to detect
CNAs involving whole chromosomes or chromosome arms is
almost 100%.
Despite the overall performance of the exome2cnv approach for
the identification of tumor-specific CNAs, an inherent limitation of
this approach when compared to aCGH data is the accurate
determination of the CNA boundaries. Thus, the distribution of
aCGH probes in high resolution arrays allows a precise estimation
of CNA boundaries within kilobase resolution. However, the
uneven distribution of exons throughout the genome results in less
accurate boundaries in terms of genomic distances, but in a highly
accurate determination of genes and exons involved in the copy
number alteration. In this regard, an alternative approach that
might be considered by the manufacturers of target-capture
reagents is the introduction of additional probes in exon-poor
regions. These extra probes would not help in the identification of
substitutions in coding regions, but would improve the estimation
of CNA length and boundaries.
Another aspect to take into consideration when using primary
tumors is the presence of normal cell contamination in the tumor
sample. Although the tumor samples used in this study had more
than 95% tumor cell content, some of the CNAs detected by our
method appeared to be present in a subpopulation of tumor cells.
These data indicates that exome2cnv is suitable for the detection of
CNAs in complex populations, as those present in most solid
tumors, in which stromal cell contamination is usually present.
Moreover, it is important to point out that copy number changes
in the tumor also complicate the identification of somatic
mutations, and a precise estimation of tumor copy number is
necessary in order to adjust mutation calling algorithms [42].
In summary, we show that copy number changes can be
accurately determined using exome sequencing, extending the
application of this widely used technique for the study of human
disease, and allowing the identification of variations outside of
target regions used for capture. This application is of particular
interest to the field of cancer genomics, as CNAs represent an
important mechanism of mutation in most cancer types. The
analysis of a large number of primary tumor exomes and aCGH
data has allowed the first determination of the sensitivity and false
discovery rate of this approach. Together, the procedure outlined
here can be used to rapidly analyze existing datasets without
additional experimental work, what will facilitate the identification
of novel CNAs implicated in cancer.
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Table S1 Comparison of somatic CNAs detected by aCGH vs.
exome2cnv to determine sensitivity.
(PDF)
Table S2 Comparison of somatic CNAs detected by exome2cnv
vs. aCGH to determine false discovery rate.
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Figure S1 Comparison of the number of exons involved
in CNAs detected by exome2cnv and aCGH.
(PDF)
Figure S2 aCGH data showing two cases (A and B) with
a deletion affecting the short arm of chromosome 18
which was detected by exome2cnv but not by aCGH
because it is present in a subpopulation of tumor cells.
For comparison, a case (C) with a deletion affecting all tumor cells
and detected by both methods is shown.
(PDF)
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